Sumitomo Mitsui Trust Holdings, Inc. Neurocrine Biosciences Inc Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $134 Billion
- Q2 2024
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 243,443 shares of NBIX stock, worth $28.8 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
243,443
Previous 252,565
3.61%
Holding current value
$28.8 Million
Previous $34.8 Million
3.79%
% of portfolio
0.03%
Previous 0.02%
Shares
19 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.68 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.19 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$545 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$292 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$280 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.3B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...